In new research from Healthspan, canagliflozin, an SGLT2 inhibitor, indirectly clears senescent cells by activating AMPK and reducing PD-L1. This metabolic reset, evident in markers of aging, suggests benefits against obesity and cardiovascular decline. Consider these insights for refining anti-aging protocols.